

Index

- Abernathy, W. 297–8
ABI *see* Association of British Insurers
Acs, Z. 298, 305
Adam, B. 138
Adelberger, K. 348
Afuah, A. 358
agro-food biotechnology 122–3
 available finance 122
 framework conditions for
 innovation 124, 128, 129
 industry/supply network 121, 122
 market 122, 129
 national innovation strengths and
 weaknesses 125–7
 public attitudes towards 116–17,
 122, 123, 129
 public investment in 121
 regulation 116, 117, 122
 technology transfer 122
Akerlof, G. 139
Allansdottir, A. 397
alliance databases 37
Almeida, P. 327, 340, 356
ambiguity 138
Anderson, P. 298
Andersson, T. 295
Anselin, L. 359
Antonelli, C. 92, 270
Arora, A. 361, 376
Arrow, K. 137, 139
Association of British Insurers (ABI)
 212, 217, 224, 227, 228
 Genetic Testing Code of Practice
 212
 Genetics and Insurance Forum
 219
 Genetics Committee 212
Association of Clinical Cytogeneticists
 145
Audretsch, D. 267, 298, 299, 302, 338,
 356, 360, 361, 377
Autant-Bernard, C. 359, 360
Barras, R. 207
Bartholomew, S. 99
Bas, T. 302
Bathelt, H. 268
Baum, J. 360
Berger, A. 312
Berkhout, F. 135
Bernstein, P. 137, 139
Binks, M. 311
biobanks 55, 60
 end-users of results 57–8
 ethical and legal issues 59
 public debate 59
 societal linkages 58
bioinformatics 87, 235, 236, 240
 see also distributed innovation
 processes; LION Bioscience
biomaterials 299–300
 categories 303–04
 patenting 300
 spatial concentration of innovative
 activities 300, 301
 technological opportunities 300
biopharmaceuticals sector
 available financing 121
 framework conditions for
 innovation 124, 128, 129
 industry/supply network 120
 markets 114–15, 120, 129
 national innovation strengths and
 weaknesses 125–7
 PINGOs, influence of 115–16
 pricing policies 115, 120
 promoting innovation 121, 129
 public sector research 119–20
 regulation 120
 research and development
 collaborations 120
 social acceptability 120, 129
 technology transfer mechanisms
 120–21
biotech clusters 352

- deregulation of financial systems 347
- flexible labour market, need for 340, 347, 349
- local-network driven 344
- location's ability to act as a magnet for commercial activities 345
- sector-specific regulation and policy 350
- technology transfer infrastructure 347, 348, 352
- universities
 - proximity to 335, 336
 - role of 332, 333, 343, 350
- venture capital accessibility 346, 347, 348
- see also* Boston; Cambridge; Munich
- biotech firms
 - absorptive capacity 360, 361, 362
 - continued collaboration with inventors 335–6
 - definitions of 33, 34
 - Europe
 - available finance 113–14
 - case study 100–102
 - distribution of firms by sector and country 103
 - distribution of firms by size and country 105, 106
 - distribution of firms by size and sector 105, 109, 110
 - foundation date of firms 103, 104, 105
 - main product markets 106–07
 - numbers of subsidiaries 107, 109
 - origins of companies 108, 109
 - research and development collaborations 108, 109
 - services offered 106
 - turnover attributable to biotechnology 106
 - financial resources
 - access to 54
 - sources of competitive advantage 326
- biotech research equipment and supplies sector
 - available finance 123, 124
 - framework conditions for innovation 124, 128, 129
 - knowledge/skills network 124
 - market 118–19, 123
 - national innovation strengths and weaknesses 125–7
 - public attitudes 123
 - regulation 119, 123
 - research investment 123, 124, 129
- biotechnology
 - application areas 21–2
 - data sources 31–7
 - limitations of 32, 37
 - definitions of 21, 22, 23
 - development of 173–4
 - generations of 24, 77
- Biotechnology Industry Organisation (BIO) 22
- Blundell, Tom 334
- Borgatti, S. 184
- Boston
 - founder scientists' relationships with companies 350, 351
 - origins of biotech firms 333
- Boutellier, R. 182, 183
- Breschi, S. 269, 297, 298, 359, 381
- Brickman, R. 117
- Brinks, J. 290
- Brisbane 277
 - business activities 284, 286, 287
 - correlation between science, technology and business activities 278
 - regional specialization 288
 - revealed scientific advantage 282, 285
 - revealed technological advantage 283, 286
- Brusco, S. 267
- Brusoni, S. 228, 229
- Bud, R. 46, 77
- Bush, V. 47
- business activities 275
 - correlation with scientific and technological activities 277, 278, 289, 290
 - measurement of 272, 273–4, 280–81
- business networks 92, 93, 94, 95, 96
- Cable, D. 318
- Callon, M. 101

- Cambridge
 biotech firms
 affiliation of scientific advisory board members 338–9
 composition of research collaborations 336–7
 employment origins of scientists 341, 342
 frequency of start-ups 333, 334
 geographic location of academic collaborators 337, 338
 geographic location of scientific advisory board members 339
 origins of 333, 334
 geographic locations of last academic job 345
 labour market flexibility 341, 342
 rules governing technology licensing 350, 351
 scientific institutions 332
 university-industry relationships 350, 351
- Carlsson, B. 23, 100, 101, 170, 171, 237, 297, 298, 326
- Casari, Georg 244
- Casper, S. 327, 329, 330, 347, 348, 350
- Catherine, D. 356
- Cellmark Diagnostics 146, 149–50, 159
 intellectual property rights 158
 market appropriation strategies 158
 market focus 146
 numbers of people tested 146
 risk management 150, 151, 152, 158
 service delivery 146
 technical competences 158
- Cetindamar, D. 51
- Chandler, A. 140, 214
- Chao, L. 115
- Cheetham, P. 174
- Christensen, C. 298
- Clarke, A. 142
- Clinical Molecular Genetics Society (CMGS) 143, 145
- co-publications 375, 376
- Cockburn, I. 52, 79, 361
- Cohen, W. 214, 228, 229, 270, 360
- Concar, D. 143
- Cooke, P. 268, 309, 319, 343, 357, 362
- Cookson, C. 156
- Coombs, R. 180, 228, 238
- Copeland, E. 144
- Cortright, J. 303, 318
- Crick, F. 332
- Crowther, S. 114
- Cytogenetics DNA Services Ltd 146, 147–8, 159
 intellectual property rights 157, 158
 market appropriation strategies 158
 market focus 146
 numbers of people tested 146
 risk management 148, 149, 158
 service delivery 146
 technical competences 158
- Dachs, B. 203
- Daniell, E. 174
- Danzon, P. 115
- Darby, M. 23
- Dasgutha, P. 272
- David, P. 272
- DBFs *see* dedicated biotechnology firms
- De la Mothe, J. 95
- deCode Genetics 59, 61
- dedicated biotechnology firms (DBFs) 23, 27
 market characteristics 79
 role of 65, 77, 78, 89–90, 95
 specialization 88
 US/European contrasts 80, 81
- Department of Health 209, 211, 212, 213
- developing countries 397, 398, 400
 companies' incentives to innovate 398, 399
 future policy requirements 400–401
 research into diseases 398, 399
 societal impacts of modern biotechnology 398
- DiMasi, J. 48
- distributed innovation processes (DIPs) 237, 238, 239
 balance of ownership and flows of knowledge 253, 254, 255
 case study
 methodology 241, 242, 261
 development and marketing of informatic applications 255
 established firms, role of 255–6

- interdependence between public and private sector 253
- privatization of software 255
- see also* LION Bioscience
- Dodgson, M. 169
- Dohse, D. 237
- Donnai, D. 145
- Dosi, G. 138
- Drew, J. 11
- Duyk, G. 174
- East Gothia 276
 - business activities 284, 286–7
 - correlation between science, technology and business activities 277, 278
 - regional specialization 288
 - revealed scientific advantage 281, 282, 285
 - revealed technological advantage 283, 285–6
- Edquist, C. 44, 100, 169, 295, 297
- Egidi, M. 138
- Eisenberg, R. 64
- Eliasson, G. 171
- Elles, R. 145
- Ennew, C. 311
- Enright, M. 301
- Enzing, C. 99
- Ernst & Young 5, 295, 327, 329, 330, 348, 349
- Espósito, R. 82
- Etzold, Thure 244, 245
- European Bioinformatics Institute (EBI) 244, 245
- European Federation of Biotechnology (EFB) 22
- European Medicines Evaluation Agency (EMA) 115
- European Molecular Biology Laboratory (EMBL) 243, 244, 245
- European Patent Office (EPO) 35
- Fagerberg, J. 46
- Faulkner, W. 238
- Faust, K. 184
- Feldman, M. 23, 298, 302, 305, 358, 359, 360, 361, 362, 377
- Ferry, G. 345
- Fields, S. 86
- firm databases 37
- firm formation 356, 403
 - concentrated organizational origins 313, 314, 316, 317–18
 - dependence on interrelated factors 297–8
 - dispersing effects of competition 363
 - financing, sources of 311–13, 318
 - focus on certain technologies and applications 316
 - regional factors 363, 380
 - companies 318
 - diversification 376–7
 - industry structure 318, 375
 - science base 305–08, 317, 318
 - specialization 363
 - research infrastructure, role of 359, 375
 - research study
 - data sources 305
 - methodology 302, 303
 - sources of initial technological opportunity 308–11
 - spatial concentration of related industries, effect of 375, 377–8
 - technology licensing office, role of 318
- first generation biotechnology 24
- Fligstein, N. 328
- food biotechnology
 - patents 174, 175, 176
 - geographic distribution of 182–3
 - research and development 181, 182
 - see also* lactic acid bacteria biotechnology
- France
 - biotech SMEs 358
 - concentration of activity in two regions 370, 373
 - development of 362
 - employee numbers 369, 370, 371–2, 373
 - firm creation 370, 375
 - markets 373
 - mean annual growth rates 370, 373
 - participation in scientific publications 369, 371–2

- research and development
 - expenditure 369, 371–2, 375
 - research study 364–9, 373–5, 391–2
 - regional characteristics 390
 - markets 388
 - organization of research 389
 - private research 387
 - public research 386
- Francis, J. 358
- Fransman, M. 238
- Freeman, C. 172, 214, 297
- Frost, T. 368
- Fujita, M. 345
- functional genomics 85
- Galambos, L. 80
- Gambardella, A. 361, 376
- Gaskell, G. 100, 117
- Genet, C. 357
- genetic testing 142, 143
 - case studies
 - data collection 136
 - methodology 136, 137
 - commercial services 145, 146
 - concerns over 143, 144
 - factors affecting support for 143–4
 - insurance
 - impact on 210, 211, 229, 230
 - regulation 211–12, 230
 - research study 214–15, 216–18, 221, 234
 - use in 208, 209, 210, 211, 213
 - predictive capacity of 209
 - public testing services 144–5, 158
 - reliability of 210
 - risk management 157, 159, 160
 - see also* Cellmark Diagnostics; Cytogenetics DNA Services Ltd; genomics companies; insurance companies; Myriad Genetics Inc.; risk management; Sciona
- Genetics and Insurance Committee (GAIC) 212
- Genetics and Insurance Research Centre (GIRC) 219, 220, 221
- GeneWatch 143, 156
- genomics companies 55, 56
 - capital markets 60–61
 - collaborative relationships 56–7, 58–9, 60
 - marketing of services 60
 - research and development
 - costs of 57
 - economic value of 57
 - scientific competencies required 56
 - specialization 88
 - see also* biobanks
- Germany
 - biotech industry 329, 330, 331
 - government promotion of biotech clusters 329
 - see also* Munich
- Geuna, A. 199
- Gibbons, M. 77
- Giesecke, S. 99
- Gilbert, Walter 83, 152
- Gökbayrak, E. 276
- Goldfarb, B. 295
- Gothenburg 276
 - business activities 284, 286, 287
 - correlation of science, technology and business activities 277, 278
 - regional specialization 288
 - revealed scientific advantage 281, 282, 285
 - revealed technological advantage 283, 286
- Grabowski, H. 78
- Granberg, A. 11
- Grannovetter, M. 349
- Granstrand, O. 229
- Green, W. 374
- Greenwood, R. 360
- Griliches, Z. 272
- growth of firms
 - determinants of 378–9, 382
 - regional environment, effect of 363, 364, 380, 381
- Gulati, R. 326, 342
- Hacking, I. 137
- Håkansson, H. 101, 297
- Hall, P. 326, 331, 346, 347
- Harhoff, D. 302, 308
- Harper, P. 142
- Harris, R. 136
- Harrison, B. 237

- Harvey, M. 238, 253
 Hawkes, N. 156
 Hayek, F. von 137
 Hecht, J. 207
 Henderson, R. 49, 99, 167, 298, 361
 Henrekson, M. 295
 HGP *see* human genome project
 Higgins, M. 326, 342
 Hoch, H. 87, 88
 Hodgman, H. 235
 Holmén, M. 290
 Holtzman, N. 143, 160
 Hopkins, M. 155
 Howitt, S. 215
 Human Genetics Advisory
 Commission (HGAC) 211–12
 Human Genetics Commission (HGC)
 210, 212
 human genome project (HGP) 82
 economic opportunities arising from
 82, 83, 84
 impact on life science industry 79
 implementation of 78–9
see also post-genome era
- Iansiti, M. 169
 IDEFI/ULB 77, 80, 81
 ignorance 138
 industrial clusters 267
 industrial districts 267
 industrial policies 112–13
 industrial sectors
 classification of 26–7
 innovation
 actors involved in 7, 50, 51, 62, 63,
 64, 65
 development of 6, 45, 61–2
 economic value of 6–7, 44–5, 48, 49,
 62
 ethical issues 51
 firms' role in 7, 62
 link with developments in science
 and technology 46, 47, 61, 402
 network of key factors influencing
 101
 networks 82, 86, 88–9, 90, 91, 94, 95,
 96
 public debates on 51–2, 62
 regulation of 51, 62
 relationship with regional public
 and private sector research
 expenditure 359
 relationship with regional
 technology transfer
 infrastructure 359
see also research and development
 Institute and Faculty of Actuaries 219
 insurance companies 215, 216
 competence building strategies 221,
 226
 importance of joint research
 programmes 224, 225, 229
 industry division of knowledge 230
 information flows 227, 228
 methods of communicating with
 external bodies 224, 225
 Nominated Genetics Underwriters
 (NGUs) 226
 sources of information for 220, 222,
 223, 224, 225, 226, 227, 228,
 229
see also genetic testing; reinsurance
 companies
 intellectual property rights (IPRs)
 84–5, 112, 157, 158
 Irvine, J. 123
- Jacobsson, S. 273, 295
 Jaffe, A. 302, 305, 359
 Jeffcoat, R. 174
 Jeffries, Sir Alec 149
 Jensen, R. 168, 169
 journal impact factor 272
 Judson, H. 174
- Kahneman, D. 137
 Kaplan, S. 329
 Katz, J. 9
 Kay, L. 46
 Kegley, J. 142
 Kenney, M. 46, 64, 123, 326, 335
 Kettler, H. 330, 348
 Kevles, D. 142
 Keynes, J. 138
 Khurana, R. 298
 Kitcher, P. 136, 143
 Kivinen, O. 99
 Klepper, S. 274
 Klevorick, A. 198
 Kline, S. 46

- Knight, F. 138
 Knorr-Cetina, K. 101
 knowledge/skills networks
 effect of government policies 110–11
 Kogut, B. 327, 340, 356
 Kopp, P. 80
 Kriss, A. 151
 Krugman, P. 267, 297, 357, 362, 363
 KSLAT 52, 53
 Küppers, G. 169

 Laage-Hellman, J. 27, 51, 55
 labour market flexibility 340, 341, 342, 347, 349
 lactic acid bacteria (LAB)
 biotechnology
 applications of 177, 178, 179, 180
 innovation systems 191–2
 nationality dimension 192–3
 patents 174, 175, 176, 177, 178, 179, 180–81
 geographic distribution of 182–3
 research and development
 cognitive dynamics 195–6
 economic competence 193–4, 195, 196–7
 national systems of 197
 organizational networks 183–4, 185–7, 188–91, 196
 skills required 181
 Lancaster, K. 27
 Landström, H. 311
 Langer, Bob 351
 Larédo, P. 199
 large incumbent firms
 leadership of the pharmaceuticals industry 403
 Latour, B. 101, 136
 Laurent, T. 80
 Laursen, K. 198
 Lazonick, W. 140
 Ledley, F. 144
 Leisner, J. 198
 Lemarie, S. 358
 Lenaghan J. 143
 Lerner, J. 326
 Leveque, F. 169
 Levett, L. 147
 Levinthal, D. 214, 228, 229, 270, 360
 Liddle, S. 147

 Liebeskind, J. 169, 306, 360
 life science industry
 business networks 92, 93, 94, 95, 96
 electronics, role of 87–8
 future research and development implications 95
 improvements in techniques 86, 87, 88
 innovation networks 82, 86, 88–9, 90, 91, 94, 95, 96
 instability of 77, 78
 interdisciplinary projects 86, 88
 large corporations
 passive role of 79–80
 mergers and acquisitions 80, 82
 public/private cooperation 77
 source of growth opportunities 91
 US/European contrasts 80, 81, 82, 96
 Lindblom, C. 47
 LION Bioscience 241, 242, 251, 257
 acquisitions
 GMD 249–50
 NetGenics 250–51
 Trega 249
 activities 246–8
 cross-licensing deal with MDL 250
 formation of 243
 GeneQuiz 244
 network of relationships 252
 partnerships
 Bayer 248–9
 Celera 254
 life science companies 242, 243
 Nestlé 254
 sequence retrieval system (SRS) 244, 245, 246
 Lissoni, F. 269, 359, 381
 Llerena, P. 169
 Loasby, B. 138
 localized knowledge spillovers 268–70, 359, 360
 Lundgren, A. 101
 Lundvall, B.-A. 172, 297
 Lynskey, M. 192

 Macdonald, A. 210
 Malecki, E. 267
 Malerba, F. 99, 237, 297, 298
 Malloy, M. 82

- Malmberg, A. 270
Mandran, N. 359, 378
Mangematin, V. 358, 359, 360, 378, 381
Margolis, J. 174
Marshall, Alfred 267
Martin, Chris 155
Martin, P. 135, 362
Martin, R. 267, 268
Martinson, J. 135
Maskell, P. 270
Massachusetts
 clustering 318, 319
 correlation between RSA and RCA 308
 firm formation
 concentrated organizational origins 313, 314, 315
 sources of financing 311, 312, 313
 sources of initial technological opportunity 309–11
 regional science base 302, 303
 influence on firm formation 307, 308
 revealed comparative advantage (RCA) 306, 307
 revealed scientific advantage (RSA) 306, 307
Massard, N. 359, 362
Matt, M. 169
Mayer, H. 303, 318
McKelvey, M. 9, 27, 37, 44, 77, 78, 80, 95, 271, 272, 276, 290, 291, 369, 375
McMeekin, A. 238, 253
McNiven, C. 34
Meek, J. 210
Melbourne 276–7
 business activities 284, 286, 287
 correlation between science, technology and business activities 278
 regional specialization 288
 revealed scientific advantage 282, 285
 revealed technological advantage 283, 286
Meldrum, Peter 152
Meredith, Rodney 147, 148
Merz, J. 151
metabolomics 25
Metcalf, S. 180
modern biotechnology
 categories of 9, 274, 275
 data sources 396
 definitions of 9, 10–11, 22, 23, 24, 25
 development of 24
 economic impact of 9–10, 11, 12
 future research requirements 396, 397
 government policies towards 63, 64
 interdisciplinarity of 46, 61
 knowledge bases 8–9, 20, 24, 28, 29, 30, 31
 limitations of studies on 4
 product-based axis of 26, 27, 28, 30, 31
 simultaneous global and local aspects of 4
 societal impacts of 3–4, 47, 395
 developing countries 398
 techniques of 25
Mogee, M. 273
Morange, M. 174, 183
Moss, D. 137, 139, 140, 152
Mowery, D. 140, 214, 229, 350
Mullis, K. 86
Munich
 biotech firms
 affiliation of scientific advisory board members 338–9
 composition of research collaborations 336–7
 employment origins of scientists 341, 342–3
 frequency of start-ups 333, 334, 335
 geographic location of academic collaborators 337, 338
 geographic location of scientific advisory board members 339–40
 origins of 333, 334, 335
 geographic locations of last academic job 345
 labour market 342
 scientific institutions 331–2
Murray, F. 327, 329, 350
Mustar, P. 199, 380
Myriad Genetics Inc. 146, 152–4, 159
 intellectual property 158
 market appropriation strategy 157, 158

- market focus 146
- numbers of people tested 146
- risk management 154, 155, 158
- service delivery 146
- technical competences 158

- Narin, F. 273
- national systems of innovation (NSI)
 - theory 100, 172, 173, 197, 198, 199
- Nelson, R. 100, 169, 172, 198, 237, 270, 297, 350
- Nesta, L. 358, 360, 368
- new economic geography 267, 268
- Nightingale, P. 25, 48, 139, 140
- Nilsson, A. 52
- Niosi, J. 54, 95, 302, 356, 378
- Noma, E. 273
- Noyons, E. 272
- Nuffield Council on Bioethics 154

- OECD *see* Organisation for Economic Co-operation and Development
- Office of Technology Assessment (OTA) 22, 27, 48

- Ohio
 - clustering 319
 - correlation between RSA and RCA 308
 - firm formation
 - concentrated organizational origins 313, 314
 - sources of financing 311, 312, 313
 - sources of initial technological opportunity 309–11
 - regional science base 302, 303
 - influence on firm formation 307, 308
 - revealed comparative advantage (RCA) 306, 307
 - revealed scientific advantage (RSA) 306, 307
- Oliver, S. 235–6
- O'Neill, O. 209
- Organisation for Economic Co-operation and Development (OECD) 4, 9, 22, 23, 24, 27, 33, 63, 143, 285
- orphan-designated products 398, 399

- Orsenigo, L. 47, 49, 78, 80, 90, 95, 99, 169, 176, 237, 297, 298, 302
- Ostro, M. 82
- Ottaviano, G. 362
- Owen-Smith, J. 238

- patents 64, 273
 - sources of data 35
- Pavitt, K. 198, 228, 273
- Payson, S. 26
- Penrose, E. 76, 91, 92
- PGE *see* post-genome era
- pharmacogenomics 85
- PINGOs 115–16, 122
- Pisano, G. 360
- Poll, R. 139, 140
- Porter, M. 267, 302, 345
- positional cloning genomics 85
- post-genome era (PGE) 76
 - challenging problems of 84–5
 - inter-organizational interactions 89
 - research areas 85–6
- Powell, W. 22, 27, 90, 91, 169, 214, 238, 326, 327, 344
- Prencipe, A. 229
- Preston, L. 305
- Prevezer, M. 29, 378
- Pridmore, R. 182
- Priest, S. 135
- probabilistic risk 138
- proteomics 25, 85
- public interest non-government organisations (PINGOs) 115–16, 122
- public-private partnerships (PPPs)
 - research into specific diseases 399, 400
- Pyka, A. 80, 173

- Quéré, M. 78, 92, 93

- R & D *see* research and development
- Raeburn, Professor 212
- Ramsden, S. 152
- Rappert, B. 238
- RCA *see* revealed comparative advantage
- regional specialization 267, 268, 269, 289, 290, 361, 362

- case studies 288
 - methodology 272–5
- dependence on co-location of
 - multiple types of activities 271
- see also* business activities; revealed comparative advantage; revealed scientific advantage; revealed technological advantage
- Reid, M. 136
- reinsurance companies
 - importance of joint research programmes 224, 225, 226
 - in-house research 220, 226, 229
 - information flows 227
 - sources of information 222, 223, 224, 226
 - see also* insurance companies
- research and development
 - costs of 48, 62, 65
 - firms' role in 52, 53, 54
 - inter-organizational 168, 169, 170
 - investment in 63, 396–7
 - networks of collaborative relationships 50, 51, 52, 54, 169
 - organizational types 50–51
 - surveys on 35–7
 - see also* innovation
- revealed comparative advantage (RCA)
 - case studies 306, 307
 - see also* revealed scientific advantage; revealed technological advantage
- revealed scientific advantage (RSA)
 - Brisbane 282, 285
 - calculation of 279–80
 - East Gothia 281, 282, 285
 - Gothenburg 281, 282, 285
 - Massachusetts 306, 307
 - Melbourne 282, 285
 - Ohio 306, 307
 - Sweden 306, 307
- revealed technological advantage (RTA)
 - Brisbane 283, 286
 - calculation of 279–80
 - East Gothia 283, 285–6
 - Gothenburg 283, 286
 - Melbourne 283, 286
- Richardson, G. 92, 93, 94
- Rickne, A. 53, 302
- Riou, S. 362
- Rip, A. 183
- risk management 137, 139, 140
 - combinations of organizations 141
 - diversification strategies 141
 - firms 140, 141
 - governments 140, 141
 - insurance and financial markets 139
 - precautionary approach to 139
 - procedures 138, 139
 - risk assessment 137, 138
 - types of risk 138
 - see also* genetic testing
- Robbins-Roth, C. 79, 80
- Roberts, E. 298
- Ronzio, C. 23, 362
- Rose, H. 139
- Roseboom, J. 183
- Rosenberg, N. 46, 199, 295
- Rosenfeld, S. 302
- Rothschild, M. 139
- Rothwell, R. 113, 140, 297
- RSA *see* revealed scientific advantage
- RTA *see* revealed technological advantage
- Rutten, H. 183
- Rybak, B. 235
- Rynning, E. 51
- Sainsbury, Lord 22
- Salminin, S. 168, 198
- Salter, A. 183, 198
- Sanger, F. 86
- Sattelle, D. 9
- Saviotti, P. 77, 80, 93, 100, 167
- Saxenian, A. 237, 268, 297, 301, 302, 327
- Schiele, H. 301, 362
- Schissel, A. 151
- Schmookler, J. 272
- Schneider, Reinhard 244
- Schreiber, Stuart 351
- Schumpeter, J. 295, 298
- scientific activities 275
 - correlation with technological and business activities 277, 278, 289, 290
 - measurement of 272, 273, 274
 - see also* revealed scientific advantage

- scientific advisory boards (SABs) 338, 339, 340
- scientific publications
as sources of data 34–5
- Sciona 146, 155–7, 159
intellectual property 158
market appropriation strategies 158
market focus 146
numbers of people tested 146
risk management 156, 157, 158
service delivery 146
technical competences 158
- Scott, A. 268
- second generation biotechnology 24
- Senghaas, D. 47
- Senker, J. 238, 329, 356
- serial entrepreneurship 319–20
- Shane, S. 297, 298, 317, 318
- Skolnick, Mark 152
- Soete, L. 172, 279
- Sorensen, O. 326
- Sörlin, S. 295
- Soskice, D. 326, 331, 346, 347
- Stankiewicz, R. 11, 170, 237, 297, 298
- Steier, L. 360
- Steinle, C. 301, 362
- Stephan, P. 267, 299, 338, 356, 360
- Stiglitz, J. 139
- Stirling, A. 135, 137, 138, 139
- Storper, M. 237, 268
- structural genomics 85
- Stuart, T. 326
- Sturchio, J. 80
- Suarez, F. 274
- Sulston, John, Dr. 332, 345
- Sunley, P. 267, 268
- surveys of firms 33, 34
- Swan, P. 29, 302
- Sweden
clustering 318, 319
correlation between RSA and RCA 307–08
firm formation
concentrated organizational origins 313, 314
sources of financing 311, 312, 313
sources of technological opportunity 309–11
revealed comparative advantage (RCA) 306, 307
revealed scientific advantage (RSA) 306, 307
science base 302, 303
influence on firm formation 307, 308
see also East Gothia; Gothenburg
- Tait, J. 116
- technological activities 275
correlation with scientific and business activities 277, 278, 289, 290
measurement of 272, 273, 274
see also revealed technological advantage
- technological platforms 90
- technological regimes (TRs) 298
determining the scope of new firms 299
implications for the innovation process 298, 299
- technology licensing offices 318, 352
- technology system (TS) theory 100, 170–71, 173, 198, 199
see also lactic acid bacteria biotechnology
- technology transfer mechanisms 111–12, 120–21, 122, 347, 348, 350, 351, 352, 359
- Teece, D. 90, 136, 141, 151, 157
- Thackray, A. 77
- third generation biotechnology *see* modern biotechnology
- Thomas, S. 155
- Törnqvist, G. 295
- trade statistics 32–3
- traditional biotechnology 24
- Trajtenberg, M. 273
- transcriptomics 85
- TRs *see* technological regimes
- Tushman, M. 298
- Tversky, A. 137
- Udell, G. 312
- UK Forum for Genetics and Insurance 219
- Ullrich, Axel, Professor 335
- UmanGenomics 59, 61
- uncertainty 138
- United Kingdom

- biotech industry 329, 330
- government promotion of
 - commercialization of university research 330
- see also* Cambridge
- United States
 - Bayh-Doyle Act (1980) 44
 - competitive advantage 4–5
 - see also* Boston; Massachusetts; Ohio
- United States Patent and Trademark Office (USPTO) 35
- universities
 - biotech clusters
 - proximity to 335, 336
 - role in 332, 333, 343, 350
 - formation of companies 335
 - government promotion of
 - commercialization of research 330
 - need to encourage serial
 - entrepreneurship and pre-firm activities 319, 320
 - relations with biotech firms
 - Cambridge 350, 351
 - geographic locations 360, 361, 362
 - research teams 50–51
- Utterback, J. 274, 297, 298, 358
- Valentin, F. 168, 169, 183
- van der Meulen, B. 183
- VanLoon, J. 138
- Varelius, J. 99
- Venables, A. 362
- venture capital
 - availability of 54, 61, 113–14, 123, 124, 311, 312, 313, 318, 346, 347, 348
 - databases 37
- Vernon, J. 78
- von Bohlen, Friedrich, Dr. 243, 250
- von Tunzelmann, G. 228
- Walsh, V. 99
- Wang, Q. 228
- Wasserman, S. 184
- Watson, J. 332
- Weber, M. 139
- Weinstein, N. 139
- West, J. 169
- Westphal, S. 154
- Whitesides, George 351
- Williamson, O. 90
- Winborg, J. 311
- Winter, Craig 334
- Winter, S. 270, 297, 305, 343
- World Health Organization (WHO) 12
- Wright, A. von 168, 198
- Wyatt, S. 279
- Wynne, B. 137, 138
- Zegveld, W. 113
- Zeller, C. 302
- Zimmern, R. 142
- Zucker, L. 23, 269, 298, 301, 302, 335, 356, 357, 361